Faron Appoints Ralph Hughes as Chief Business Officer (CBO)

Ralph Hughes joins Faron to strengthen Commercial Strategy, Business Development and Market Assessment function

Turku, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company advancing next-generation immunotherapies, is pleased to announce the appointment of Ralph Hughes as the new Chief Business Officer, starting on the 28 May 2025. Mr. Hughes will be part of the Management Team and Business Development Committee.

Prior to joining Faron, Mr. Hughes worked as Senior Vice President at PharmaVentures, serving multiple clients with expertise in Commercial Strategy, Business Development and Market Access.

• Hughes has extensive experience in commercial due diligence, market access and business development processes through his various roles in the pharmaceutical industry. At Mundipharma, he was responsible for the commercial launch strategy for pipeline assets and commercial assessment of new assets. At Pfizer, he developed global commercial, market access and pricing strategies across multiple disease areas for early-stage and in-market assets.
• Hughes holds an MSc in Public Health and Health Economics from the London School of Hygiene and Tropical Medicine, and a BSc in Biomedical Sciences from Newcastle. Throughout his career, Mr. Hughes has developed a strong understanding of what it takes to overcome access hurdles and commercialize novel therapeutics.

“I am honoured to step into this role at such a critical time for Faron”, says Mr. Hughes the in-coming CBO of Faron. “I look forward to putting my experience to good use and fostering partnerships that will further the Company’s mission and fulfil our promise of bringing this exciting immunotherapy closer to patients”

“We are delighted to have such an experienced pharmaceutical market access and strategic commercial development expert to join us as the new CBO”, says Dr. Juho Jalkanen, CEO of Faron. “Ralphs’s proven track record in biopharma leadership and his experience aligns perfectly with our corporate development efforts and strategic growth initiatives.”

About bexmarilimab